checkAd

     109  0 Kommentare Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies - Seite 3

    Contact:

    Secarna Pharmaceuticals GmbH & Co. KG
    Alexander Gebauer, MD, PhD
    CEO
    alexander.gebauer@secarna.com
    Secarna Pharmaceuticals GmbH & Co. KG
    Am Klopferspitz 19
    82152 Planegg/Martinsried
    Tel.: +49 89 215 46 375

    For media enquiries
    Anne Hennecke/Vera Lang
    MC Services AG
    Secarna@mc-services.eu
    Tel.: +49 211 529252 15

    Celanese Corporation

    Investor Relations
    Brandon Ayache
    +1 972 443 8509
    Brandon.ayache@celanese.com

    Media Relations - Global
    Brian Bianco
    +1 972443 4400
    media@celanese.com

    SOURCE: Secarna Pharmaceuticals GmbH & Co. KG



    View the original press release on accesswire.com


    The Celanese Stock at the time of publication of the news with a fall of -0,07 % to 149,3EUR on Tradegate stock exchange (19. März 2024, 22:26 Uhr).
    Seite 3 von 3



    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von Accesswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies - Seite 3 DALLAS, TX and MARTINSRIED, GERMANY / ACCESSWIRE / March 20, 2024 / Celanese Corporation (NYSE:CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery …